- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Key Takeaways from Experts in Heart Failure Management
The panelists provide their closing thoughts, highlighting their key takeaways from their discussion about updates in heart failure management.
EP: 1.Identifying Key Risk Factors for Heart Failure
EP: 2.Socioeconomic Factors Impacting Development of Cardiac Disease
EP: 3.Distinguishing Between Heart Failure Classifications
EP: 4.Staging Heart Failure and the Importance of Early Diagnosis
EP: 5.The Role of the Primary Care Physician in Heart Failure Management
EP: 6.Four Pillars of Heart Failure Therapy
EP: 7.Selecting Optimal First-line Therapy for Patients Diagnosed with Heart Failure
EP: 8.Key Takeaways From Heart Failure Clinical Trials
EP: 9.Navigating the Patient Journey Through Heart Failure Diagnosis
EP: 10.Strategies for Treating Preserved Ejection Fraction (HFpEF)
EP: 11.Treatment Optimization Challenges Associated With Heart Failure
EP: 12.Financial Barriers Impeding Optimal Heart Failure Treatment
EP: 13.Trajectory of Heart Failure Treatment Strategies
EP: 14.Key Takeaways from Experts in Heart Failure Management
This is a video synopsis/summary of a panel discussion involving Robert Groves, MD; Eugene E. Wright Jr, MD; Nancy Albert, PhD, CCNS, CCRN, CHFN, NE-BC, FAHA, FCCM, FHFSA, FAAN; Nihar Desai, MD, MPH; and Kelly Marie Axsom, MD.
In closing thoughts, Desai reiterates the urgency of maximizing guideline-directed medical therapy at every patient encounter to prevent hospitalizations. Albert emphasizes that knowledge must stay current as evidence rapidly evolves. Axsom advises using multidisciplinary teams to support patients with complex heart failure. Hospitalization is a sentinel event warranting intensified therapy. Wright stresses beginning optimized therapy early and not waiting for adverse events. Overall, the informative discussion highlights key priorities such as timely intensification of treatment, using multidisciplinary teams, and staying abreast of the latest evidence. The panelists thank the audience and reaffirm their commitment to advancing patient care through education and sharing expertise.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
EHA Plenary Abstracts Zoom in From Investigational Drugs to Molecular Signatures
June 14th 2025Abstracts presented during the plenary session of the 2025 European Hematology Association (EHA) Congress spanned from novel drug regimens for myeloma and lymphoma to investigation of leukemias on the molecular and genetic levels.
Read More
COVID-19 Deaths Cloud Interpretation of Acalabrutinib-Venetoclax Combo Results
June 13th 2025A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings in a cross-trial comparison were complicated by the inclusion of deaths related to COVID-19.
Read More
Measurable Residual Disease in Decision-Making: An Opportunity, but Not a Promise
June 13th 2025Skepticism still persists around the use of measurable residual disease (MRD) for clinical and regulatory decision-making in the European context, but panelists explained the next steps that are required to advance the use of MRD.
Read More
